The report will be delivered in 2-3 business days.

Oral Biologics & Biosimilars Market Global Report 2020

Starting Price : $ 4000.00 | Pages : 200 | Published : April 2020 | SKU CODE : 7616 | Format :


The oral biologics and biosimilar market consist of sales of oral biologics and biosimilar products and related services used to treat chronic diseases such as diabetes, arthritis, cancer. Biologics are drugs made from living cells using highly complex technology while biosimilars are created to function similarly to biologics but are not identical to biologics. Biosimilars offer active properties as any licensed biologic drug. The oral biologics and biosimilar market comprise of biologics and biosimilar drugs taken orally for the targeted treatment of Alzheimer`s, multiple sclerosis, HIV/AIDS and other serious conditions.

The global oral biologics & biosimilars market was worth $1.15 billion in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 34.31% and reach $3.74 billion by 2023.

The oral biologics and biosimilar market covered inthis report is segmented by therapy into lymphocyte modulators, interleukin inhibitors, tumor necrosis factor-alpha inhibitors. It is also segmetned by disease into asthma, crohn’s disease, carcinoma, arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, sarcoma, psoriasis and others.

The rising prevalence of chronic diseases such as arthritis, asthma, cancer is expected to be a major driver of the oral biologics and biosimilar market. Long working hours, limited physical activity, unhealthy eating and drinking habits contribute to the prevalence of chronic diseases and biologics are increasingly used to treat these chronic diseases. Biologics activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body. According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biologics and biosimilars, thus driving the biologics and biosimilar market.

Stringent regulations imposed on approval of biosimilar is anticipated to hinder the growth of oral biologics and biosimilar market in the forecast period. The governments of different regions impose different rules regarding the production and use of biologics and biosimilars. Further, issues such as patent infringement or agreement issues restrict the manufacturers of biologics and biosimilars from commercializing the government-approved biosimilars. The US Food and Drug Administration requires a double regulatory approval for biosimilars, restricting the use of biosimilars as an interchangeable drug to biologics whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics. In February 2019, out of the total 17 approved biosimilars only 7 biosimilars including 4 originating biologics could enter the US commercial market. The robust government policies for approval of these drugs impact the manufacturers in oral biologics and biosimilar market.

The latest trend in the oral biologics and biosimilar market is the creation of new insulin biosimilars. The key players operating in the oral biologics and biosimilar market are investing in creating a biosimilar copy of insulin. This is also promoting competition among various biosimilar manufacturers. Following the trend, Mylan, a USA based pharmaceuticals company, in partnership with Biocon launched biosimilar insulin glargine named Semglee, in 2019 in Australia. Biocon is an Indian based biopharmaceutical company. In 2019, Oramed Pharmaceuticals, a Jerusalem based pharmaceutical company developed an oral insulin drug named ORMD-0801 to treat type 2 diabetes. Thus, companies in the oral biologics and biosimilar market are investing in the trend of developing biosimilar of insulin to gain profit.

The major players in the global oral biologics & biosimilars market are Novartis, Rani Therapeutics,  Eli Lilly and Co., AstraZeneca plc, Novo Nordisk A/S,  Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma,  Entera Bio Ltd., Allergan plc,  Emisphere Technologies,  Enteris BioPharma, Chiasma, Allena Pharmaceuticals, Gelgen, Ganlee, 3sbio, Innovent, Retractable Technologies, Inc., Changchun High Tech, Dong Bao, CP Guojian, GlaxoSmithKline Plc., Concord Biotech, Aurobindo Pharma Ltd., H. Lundbeck A/S, Sanofi-Aventis, Roche

The countries covered in the global oral biologics & biosimilars market report are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia

The Global Oral Biologics and Biosimilars Market is segmented: 1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors 2) By Disease: Asthma, Crohn`S Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others

    1. Executive Summary

    2. Oral Biologics & Biosimilars Market Characteristics

    3. Oral Biologics & Biosimilars Market Size And Growth

    3.1. Global Oral Biologics & Biosimilars Market Historic Market, 2015 - 2019, $ Billion

    3.1.1. Drivers Of The Market

    3.1.2. Restraints On The Market

    3.2. Global Oral Biologics & Biosimilars Market Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion

    3.2.1. Drivers Of The Market

    3.2.2. Restraints On the Market

    4. Oral Biologics & Biosimilars Market Segmentation

    4.1. Global Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Lymphocyte Modulators

    Interleukin Inhibitors

    Tumor Necrosis Factor-Alpha Inhibitors

    4.2. Global Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Asthma

    Crohn`S Disease

    Carcinoma

    Arthritis

    Diabetes

    Multiple Myeloma

    Enterocolitis

    Multiple Sclerosis

    Sarcoma

    Psoriasis and Others

    5. Oral Biologics & Biosimilars Market Regional And Country Analysis

    5.1. Global Oral Biologics & Biosimilars Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    5.2. Global Oral Biologics & Biosimilars Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    6. Asia-Pacific Oral Biologics & Biosimilars Market  

    6.1. Asia-Pacific Oral Biologics & Biosimilars Market Overview  

    6.2. Asia-Pacific Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    7. China Oral Biologics & Biosimilars Market  

    7.1. China Oral Biologics & Biosimilars Market Overview  

    7.2. China Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

    8. India Oral Biologics & Biosimilars Market  

    8.1. India Oral Biologics & Biosimilars Market Overview  

    8.2. India Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    9. Japan Oral Biologics & Biosimilars Market  

    9.1. Japan Oral Biologics & Biosimilars Market Overview  

    9.2. Japan Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    10. Australia Oral Biologics & Biosimilars Market  

    10.1. Australia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    11. Indonesia Oral Biologics & Biosimilars Market  

    11.1. Indonesia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    12. South Korea Oral Biologics & Biosimilars Market  

    12.1. South Korea Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    13. Western Europe Oral Biologics & Biosimilars Market  

    13.1. Western Europe Oral Biologics & Biosimilars Market Overview

    13.2. Western Europe Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    14. UK Oral Biologics & Biosimilars Market  

    14.1. UK Oral Biologics & Biosimilars Market Overview

    14.2. UK Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    15. Germany Oral Biologics & Biosimilars Market  

    15.1. Germany Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    16. France Oral Biologics & Biosimilars Market  

    16.3. France Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    17. Eastern Europe Oral Biologics & Biosimilars Market  

    17.1. Eastern Europe Oral Biologics & Biosimilars Market Overview

    17.2. Eastern Europe Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    18. Russia Oral Biologics & Biosimilars Market  

    18.1. Russia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    19. North America Oral Biologics & Biosimilars Market  

    19.1. North America Oral Biologics & Biosimilars Market Overview

    19.2. North America Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    20. USA Oral Biologics & Biosimilars Market  

    20.1. USA Oral Biologics & Biosimilars Market Overview

    20.2. USA Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    21. South America Oral Biologics & Biosimilars Market  

    21.1. South America Oral Biologics & Biosimilars Market Overview

    21.2. South America Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    22. Brazil Oral Biologics & Biosimilars Market  

    22.1. Brazil Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    23. Middle East Oral Biologics & Biosimilars Market  

    23.1. Middle East Oral Biologics & Biosimilars Market Overview

    23.2. Middle East Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    24. Africa Oral Biologics & Biosimilars Market  

    24.1. Africa Oral Biologics & Biosimilars Market Overview

    24.2. Africa Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    25. Oral Biologics & Biosimilars Market Competitive Landscape And Company Profiles

    25.1. Oral Biologics & Biosimilars Market Competitive Landscape

    25.2. Oral Biologics & Biosimilars Market Company Profiles

    25.2.1. Novartis

    25.2.1.1. Overview

    25.2.1.2. Products and Services

    25.2.1.3. Strategy

    25.2.1.4. Financial Performance

    25.2.2. Rani Therapeutics

    25.2.2.1. Overview

    25.2.2.2. Products and Services

    25.2.2.3. Strategy

    25.2.2.4. Financial Performance

    25.2.3.  Eli Lilly and Co.

    25.2.3.1. Overview

    25.2.3.2. Products and Services

    25.2.3.3. Strategy

    25.2.3.4. Financial Performance

    25.2.4. AstraZeneca plc

    25.2.4.1. Overview

    25.2.4.2. Products and Services

    25.2.4.3. Strategy

    25.2.4.4. Financial Performance

    25.2.5. Novo Nordisk A/S

    25.2.5.1. Overview

    25.2.5.2. Products and Services

    25.2.5.3. Strategy

    25.2.5.4. Financial Performance

    26. Key Mergers And Acquisitions In The Oral Biologics & Biosimilars Market

    27. Oral Biologics & Biosimilars Market Trends And Strategies

    28. Oral Biologics & Biosimilars Market Future Outlook and Potential Analysis

    29. Appendix

    29.1. Abbreviations

    29.2. Currencies

    29.3. Research Inquiries

    29.4. The Business Research Company

    29.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2015-2019, $ Billion
  • Table 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 3: Global Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 4: Global Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 5: Global Oral Biologics & Biosimilars Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 6: Global Oral Biologics & Biosimilars Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 7: Asia-Pacific, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 8: China, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 9: India, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 10: Japan, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 11: Australia, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 12: Indonesia, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 13: South Korea, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 14: Western Europe, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 15: UK, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 16: Germany, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 17: France, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 18: Eastern Europe, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 19: Russia, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 20: North America, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 21: USA, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 22: South America, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 23: Brazil, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 24: Middle East, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 25: Africa, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 26: Novartis Financial Performance
  • Table 27: Rani Therapeutics Financial Performance
  • Table 28:  Eli Lilly and Co. Financial Performance
  • Table 29: AstraZeneca plc Financial Performance
  • Table 30: Novo Nordisk A/S Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2015-2019, $ Billion
  • Figure 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 3: Global Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 4: Global Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 5: Global Oral Biologics & Biosimilars Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 6: Global Oral Biologics & Biosimilars Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 7: Asia-Pacific, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 8: China, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 9: India, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 10: Japan, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 11: Australia, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 12: Indonesia, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 13: South Korea, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 14: Western Europe, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 15: UK, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 16: Germany, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 17: France, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 18: Eastern Europe, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 19: Russia, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 20: North America, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 21: USA, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 22: South America, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 23: Brazil, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 24: Middle East, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 25: Africa, Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 26: Novartis Financial Performance
  • Figure 27: Rani Therapeutics Financial Performance
  • Figure 28:  Eli Lilly and Co. Financial Performance
  • Figure 29: AstraZeneca plc Financial Performance
  • Figure 30: Novo Nordisk A/S Financial Performance
New Drug Innovations In The Pharmaceuticals Market
Antithrombotic Drugs Are Being Used To Prevent Various Disorders
Increasing Rate Of The Elder Population Is Driving The Ophthalmology Drugs Market
Innovations In The Diabetes Therapies Market
Allergan plc- One Of The Largest Companies In The Global Drugs For Benign Prostatic Hypertrophy Market
Innovation And Development Of Combination Drugs To Enhance Growth Of The Ovarian Cancer Drugs Market
The Global Prostate Cancer Drugs Market Will Reach Around $10 By 2022
Antivirals Are The Largest And Fastest Growing Segment Of The Anti-Infective Drugs Market
Ophthalmology Drugs Market By Type (Antglaucoma Drugs, Dry Eye Medication And Other Ophthalmological Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores And Others), By Drug Classification (Branded Drugs And Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Personal Care Services Market Report - By Type (Beauty Salons, Spas & Massage, Diet And Weight Reducing Centers, Other Personal Care Services), By End User Location (On Premise, Off Premise), By Age ( Below 15, 15-40, 40-65, Above 65), By Gender (Female, Male) And By Regions | Global Market Opportunities And Strategies To 2030
View Report
Dry Eye Medication Market By Type (Aqueous Dry Eye Syndrome, Evaporative Dry Eye Syndrome), By End-User (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies), By Product Type (Liquid Drops, Gel, Liquid Wipes, Eye Ointment) And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Coronavirus (COVID-19) Current Therapy Market Global Report 2020: COVID 19 Growth And Change
View Report
COVID19 Drug Associated APIs Market Global Report 2020: COVID 19 Growth And Change
View Report
COVID19 Vaccine & Therapeutics Clinical Trial Analysis 2020
View Report
COVID19 Vaccine And Therapeutics Pipeline Analysis 2020
View Report
Remdesivir Market Global Report 2020-30: COVID 19 Growth and Change
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)